Replies to post #799618 on NorthWest Biotherapeutics Inc (NWBO)

[pqr]

Thank you for explaining this point.  

[sukus]

I see. Maryland and Virginia will be like South San Francisco, a premier for biotech R&D.

AI Grok confirmed:
Yes, South San Francisco (often abbreviated as South SF or SSF) is one of the world’s premier locations for biotechnology research and development (R&D). It’s widely recognized as the “birthplace of biotechnology” due to the founding of Genentech there in 1976, which pioneered recombinant DNA technology. Today, it’s a dense biotech cluster with over 250 companies, more than 12 million square feet of lab space, and a collaborative ecosystem that drives innovation in areas like drug discovery, cell and gene therapies, immunotherapy, and precision medicine.
Key Highlights:
• Major Players and Facilities: Home to headquarters and R&D centers for giants like Genentech (a Roche subsidiary), Gilead Sciences, and Amgen, alongside innovative startups such as Denali Therapeutics (neurodegenerative diseases), ArsenalBio (immunotherapy), and 3T Biosciences (solid tumor treatments). Recent expansions include Astellas Pharma’s $90 million West Coast Innovation Center (opened in 2024) for cell and gene therapy R&D, and AstraZeneca’s facility housing 400 R&D staff.
• Economic Impact: The area supports over 96,000 life sciences jobs in the broader Bay Area, with SSF at its core. It’s bolstered by proximity to universities like UCSF and Stanford, venture capital, and industry groups like the California Life Sciences Association (headquartered in SSF).
• Infrastructure and Growth: The city has invested $300+ million in biotech-friendly upgrades (e.g., water, sewer, and transit systems). Specialized facilities like Mispro’s vivarium labs cater to preclinical R&D needs.
This concentration makes SSF a top choice for biotech firms seeking talent, partnerships, and cutting-edge infrastructure, contributing to 27% of U.S. life sciences employment in the region.

[flipper44]

And my point at the end of my last post to you was that based upon the fact the move would otherwise not be an economically efficient move, it therefore demonstrates, imo, the April moves were required in order to prepare for commercialization. In other words, imo, they would not have made the Unity Campus move unless they were already confident at the time regarding their MAA. (CEOs are often given enough information by regulators in order to make major next step preparations)

Follow that with the London site closing, which was further from Sawston.

Follow that with the Advent Acquisition, which allows prioritization toward the DCVax platform and its combinations.

Follow that with Eden C lab suite construction initiation, knowing Eden is dedicated to L for the foreseeable future, and L is ripe for an MHRA decision. (Again, CEOs are often informed by regulators to the extent they can start preparing for next steps)